title: [Hepatitis C in hemophiliac patients in Maracaibo, Venezuela].
abstract: Infection with the hepatitis C virus is one of the risks of transfusion therapy. Considering that in Venezuela, there are not enough data that permit one to establish the frequency of hepatitis C in transfused patients, the purpose of this work was to investigate the presence of anti hepatitis C virus (HCV) antibodies in 56 hemophilic patients from Zulia State, Venezuela. Thirty six (64%) had received fresh frozen plasma and/or cryoprecipitate. Another fourteen (25%) also received lyophilized F VIII or prothrombin complex; six patients (10%) were never transfused. The positive samples (EIA 2nd. generation) were reconfirmed by RIBA-2. Twenty two of the patients were positive for HCV. The presence of anti-HCV antibodies was mainly detected in patients that received more than 10.000 U of the deficient factor. Four of the patients with HCV were also positive for the Human Immunodeficiency Virus (HIV). The results suggest that although the transfusion of blood derivatives carries the risk of HCV transmission, our patients show a low prevalence of this disease, probably due to the infrequent use of clotting factors lyophilizates.
authors.affiliation: Instituto de Investigaciones Clínicas, Universidad del Zulia, Maracaibo, Venezuela.
authors.forename: M
authors.initials: M
authors.lastname: Arteaga-Vizcaíno
authors.forename: L
authors.initials: L
authors.lastname: Blitz-Dorfman
authors.forename: J M
authors.initials: JM
authors.lastname: Echeverría
authors.forename: P
authors.initials: P
authors.lastname: León
authors.forename: J
authors.initials: J
authors.lastname: Weir-Medina
authors.forename: M
authors.initials: M
authors.lastname: Diez-Ewald
authors.forename: G
authors.initials: G
authors.lastname: Vizcaíno
authors.forename: E
authors.initials: E
authors.lastname: Torres
authors.forename: L
authors.initials: L
authors.lastname: Porto-Espinoza
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D005169:Factor VIII / Q000009:adverse effects; D006467:Hemophilia A / Q000453:epidemiology*; D002836:Hemophilia B / Q000453:epidemiology*; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000453:epidemiology* / Q000635:transmission; D018937:Hepatitis C Antibodies; D006801:Humans; D015995:Prevalence; D016036:Seroepidemiologic Studies; D065227:Transfusion Reaction; D014687:Venezuela / Q000453:epidemiology
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D005169:Factor VIII